Connect with us


Human trials for a COVID-19 vaccine candidate start in Italy

The first healthy volunteer received, in the Roman hospital, the vaccine designed by the biotech company Reithera of Castel Romano. The company was funded with $9.46 million (€8 million) by the Lazio Region and the Ministry of Research with the National Research Council to develop the vaccine. This first phase will be followed by two more, conducted on larger numbers of individuals.



This picture show a COVID-19 vaccine.

On August 24th, the human trial of a candidate vaccine for COVID-19 started in Italy with the first dose administered. The first healthy volunteer received, at the National Institute for Infectious Diseases Spallanzani in Rome, the vaccine designed by the biotech company Reithera of Castel Romano and funded with $9.46 million (€8 million) by the Lazio Region and Ministry of Research with the National Research Council. Thus also in Italy, the tests designed to give an initial response on the safety of the drug are starting.

Find out more about the first human trials that have just started in Italy for a COVID-19 vaccine candidate and read the most important economic news in the world with the Born2Invest mobile app.

The candidate vaccine will be administered to 90 volunteers in a first phase

This first phase will be followed by two more, conducted on larger numbers of individuals to give the answers on effectiveness. Monday, August 24th, the candidate vaccine called Grad-CoV2 was administered to a single person, which after vaccination is kept under observation for a few hours.

After four days, it is expected to administer the vaccine to two other people, then to four others, and so on to an increasing number of volunteers, up to 90 expected in this phase 1. It is expected to start with those who are under 55 years and to arrive only later to those over 65.

The volunteers will be split in two groups

According to the protocol established by the Italian Medicine Agency (Aifa) the 90 volunteers are organized in two groups: one of 45 healthy individuals aged between 18 and 55 years and one of 45 healthy individuals aged between 65 and 85 years. Each age group is divided into three subgroups of 15, each of which will receive three increasing doses. 

The vaccine, which involves a single administration, is one of the two designed in Italy (the other is that of the biotech company Takis, also from Castel Romano) and is based on a virus made harmless and unable to multiply, used as a shuttle to transport the genetic information that corresponds to the Spike protein, the weapon that the Sars-CoV2 virus uses to invade cells. The shuttle virus is part of the adenovirus family, the same family to which the cold virus belongs, and is of animal origin.

COVID-19 is a gorilla virus

It is a gorilla virus and, compared to its human analogue, has the advantage of not being recognized by antibodies in order to reach undisturbed the cells to which it is directed to deliver its load. Once it reaches its destination, the genetic fragment corresponding to the Spike protein will stimulate the cells to produce only that fragment of the protein, which in turn will stimulate the production of antibodies. 

Tests conducted so far on mice indicated that the vaccine is able to both stimulate the production of neutralizing antibodies, and the response of immune cells called killer T lymphocytes, capable of recognizing the cells affected by the virus.

The company Reirhera of Castel Romano

The vaccine has been studied by the company Reithera and the Spallanzani Institute. The realization and production were carried out by Reithera, an Italian biotech company located in the technopole of Castel Romano. The company is 100% Swiss owned but operates in Italy with Italian personnel. If the trial is successful the vaccine could be ready by spring 2021.


(Featured image by TheDigitalArtist via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Il Sole 24 ORE, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Suzanne Mitchell juggles the busy life of a full-time mom and entrepreneur while also being a writer-at-large for several business publications. Her work mostly covers the financial sector, including traditional and alternative investing. She shares reports and analyses on the real estate, fintech and cryptocurrency markets. She also likes to write about the health and biotech industry, in particular its intersection with clean water and cannabis. It is one of her goals to always share things of interest to women who want to make their mark in the world.